Speed and Location Both Matter: Antigen Stimulus Dynamics Controls CAR-T Cell Response

Can Liu1, Timothy Qi1, J. Justin Milner2, Yong Lu3 and Yanguang Cao1,2*

1 Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 2 Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 3 Department of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, NC, United States

Despite the success in B-cell malignancies, chimeric antigen receptor (CAR)-T cell therapies have not yet demonstrated consistent efficacy across all patients and tumor types, particularly against solid tumors. Higher rates of T cell exhaustion are associated with inferior clinical outcomes following CAR-T cell therapy, which is prevalent in solid tumors. T cell exhaustion may originate from persistent and chronic antigen stimulation by tumor cells that resist and/or evade T cell-mediated killing. We exploited CAR-T exhaustion with a classic negative feedback model (incoherent feedforward loop, IFFL) to investigate the balance between CAR-T cell activation and exhaustion under different antigen presentation dynamics. Built upon the experimental and clinical data, we hypothesize that the speed and anatomical location of antigenic stimulation are both crucial to CAR-T cell response. Chronic antigenic stimulation as well as the harsh tumor microenvironment present multiple barriers to CAR-T cell efficacy in solid tumors. Many therapeutic strategies are individually insufficient to improve of CAR-T responses against solid tumors, as they clear but one of the many barriers CAR-T cells face in solid tumors. A combination strategy targeting multiple barriers holds promise to improve CAR-T therapy in solid tumors.

Keywords: CAR-T exhaustion, CAR-T activation, antigen presentation, discontinuity theory, solid tumor

INTRODUCTION

Chimeric antigen receptor (CAR)-T cells are T cells that are genetically engineered to specifically recognize and lyse cells expressing their cognate antigen (1). Despite their rousing success in hematological malignancies, CAR-T therapies have not yet demonstrated reproducible efficacy across all patients and cancer types, particularly against solid tumors (2). CAR-T cells face multiple challenges in the solid tumor setting, including, but not limited to, the lack of truly tumor-specific antigens and the presence of hostile tumor immune microenvironments (3, 4). These challenges must be adequately addressed for CAR-T therapies to achieve success in solid tumors.

CAR-T cell functions are markedly impaired once they enter the exhaustion state. This cellular state is characterized by upregulation of inhibitory receptors (e.g., PD-1), specific epigenetic landscape and metabolism, and loss of effector function (5). The onset of exhaustion can lead to
treatment resistance and/or cancer recurrence after CAR-T cell therapy. In addition to the tonic signaling that leads to variable levels of T cell exhaustion prior to antigen encounter, mounting evidence has shown that chronic and persistent antigen stimulation can induce T cell exhaustion, consistent with the basic working principle underlying the immune system known as the “discontinuity theory” (6–8). According to the “discontinuity theory”, the dynamics of antigen exposure play critical roles in activating T cells and their effector functions. This theory stems from the observation that the immune responses are more effectively induced by sudden changes in antigen concentration, whereas chronic and prolonged exposure to antigen leads to immune tolerance or cell exhaustion (9). Like endogenous T cells, CAR-T cells also drive the same types of programs seen in chronic and prolonged antigenic exposures that can result in exhaustion phenotypes (10–13).

This study employs a classic incoherent feedforward loop (IFFL) to revisit the “discontinuity theory” of immunity and extend it to CAR-T cell therapy. The impaired functionality of CAR-T cells upon chronic and prolonged stimulation by tumor antigens is likely associated with the presence of multiple regulatory feedback systems (14). A vital feature of the IFFL is that responses are proportional to the fold-change rather than the absolute change of a stimulus, much akin to Weber’s Law (15, 16). Here, we apply an IFFL to compare CAR-T cell activation and exhaustion under the distinct dynamics of antigen stimulus in hematological, as well as in solid tumor settings for exploring their distinct levels of response. The opportunities and limitations of prospective CAR engineering and therapeutic strategies are also evaluated to aid optimal design of solid tumor CAR-T cell therapeutics.

**METHODS AND RESULTS**

**The IFFL Recapitulates Negative Regulatory Mechanisms of CAR-T Cell Function**

Antigen engagement is a requisite step for CAR-T cell activation. Down-regulation of tumor antigen can lead to resistance to CAR-T cell therapy (17). However, continuously challenging CAR-T cells with antigen often results in dampened CAR-T function (18). Reduced CAR-T cell function at high target cells and tumor antigen densities have been shown in cell lysis assays and the per-unit diminution of CAR-T cell lytic capacity is evident as target density approaches an upper boundary (Figure 1A) (19–24). The loss of cytolytic function upon repeated antigen stimulation is also observed (Figure 1B) (25) and the dampened CAR-T function is even more apparent in cytokine secretion studies (Figure 1C) (26). This dampening highlights the critical role played by negative regulators of CAR-T cellular machinery (28).

Multiple mechanisms are possibly involved in CAR-T cell activation and exhaustion. The regulatory mechanisms of CAR-T adaptation, herein defined as the progressive loss of response to chronic and constant stimulus, are multifaceted and both CAR-T cell-intrinsic and -extrinsic. Figure 1D (left) shows that cell-intrinsic mechanisms can include surface CAR internalization and negative regulation of key downstream signaling elements. Downregulation of surface CAR has been broadly reported in many studies, especially after prolonged challenges with target cells (14, 29). CAR downregulation usually occurs immediately upon antigen binding, preventing CAR-T cell hyperactivation but also diminishing subsequent target-seeking ability. On the contrary, inhibiting lysosomal degradation markedly repressed CAR downregulation and promoted their long-term killing capacity (30). The degree of T cell adaptation caused by receptor (TCR or CAR) down-regulation is highly dependent on the antigen affinity (14). Antigens with stronger binding affinities result in higher and more durable TCR or CAR engagements, potentially leading to an elevated receptor down-regulation and T cell adaptation, similar as CAR-T cell adaptations at high antigen densities. Intracellularly, the regulators of intracellular signaling pathways include a diverse pool of tyrosine kinases, phosphatases, and transcriptional factors. For instance, upon antigen stimulation, LCK activates both the activating tyrosine kinase ZAP70 and its inhibitor SHP1 in what is referred to as the LCK-ZAP70-SHP1 loop, which leads to a rapid attenuation of T cell activation (31).

A second regulatory feedback mechanism is the upregulation of a repertoire of immune inhibitory receptors (Figure 1D, middle). Exhausted CAR-T cells express multiple inhibitory receptors (e.g., programmed cell death 1, PD1) that regulate effector function. These co-inhibitory receptors can be classified into various families on the basis of their structure and functions, wherein spatiotemporal expression curtail T cell functions in a highly context-dependent manner. Finally, the tumor microenvironment is rich with immune suppressive cells, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), tumor associated macrophages (TAMs), and cancer associated fibroblasts (CAFs) (Figure 1D, right). These extrinsic regulatory mechanisms can considerably diminish CAR activation and cause CAR-T cell exhaustion by expressing and secreting inhibitory factors (32, 33). Indeed, while these diverse cell-intrinsic and -extrinsic regulatory mechanisms ensure contextually-appropriate behavior for endogenous T cells, in the tumor they form the biological basis for CAR-T cell exhaustion.

Many studies have characterized the transcriptional and epigenetic alterations that define CAR-T cell exhaustion (34, 35). Here we focus on antigen stimulus dynamics and its influence on CAR-T activation using a reduced modeling framework – IFFL. We employ IFFl to interrogate intrinsic and extrinsic regulators of CAR-T cell exhaustion (27). We implemented the model in R, and the model equations and parameters are both provided in Supplementary Material. As depicted in Figure 1E, input (X), representative of tumor antigenic stimulation, can directly activate CAR-T cells (Z) while indirectly repressing CAR-T cell functions (Z) through a suite of multiple intermediate negative regulator (Y) as depicted in Figure 1D.

In the IFFL, when the input X is presented constantly, a transient increase of output Z is observed due to the temporal delay in repressor Y accumulation. As repressor Y accumulates, the output Z returns to baseline – perfectly, in the case of perfect
adaptation. IFFL is a fundamental network motif broadly observed in biological sensory systems (e.g., vision and hearing) as well as gene regulation, in which an activator regulates both a gene and its repressor of the gene (36). Similar frameworks have been broadly applied to describe the regulatory nature of the immune system, particularly the T cell response (9).

In the context of CAR-T cells, we apply IFFL to recapitulate antigen-dependent CAR-T cell activation and exhaustion. Antigen Presentation Dynamics Influences CAR-T Cell Response

Mounting experimental evidence supports fold-detection as a feature of the immune system in pathological contexts such as cancer, viral infection, and allergies (8). One feature of the IFFL is fold-change detection, in which a response depends on the fold-change of the input, rather than on its absolute level. As shown in Figure 2A, two patterns of stimuli with five-fold increases from different baselines result in identical responses. This fold-change detection is the basis of “discontinuity theory” in the immune system. Importantly, this feature imbues CAR-T cells with high sensitivity to relative changes in antigen stimulus that can ultimately shape their response (9).

Antigen stimulus dynamics are a function of the interaction kinetics between CAR-T and tumor cell, which is extremely variable among cancer patients and contributes to the high variability in CAR-T cell proliferation and response. Within the IFFL, we simulated CAR-T cell responses by fixing total antigen stimulus exposures (equivalent total exposure of input X) and varying temporal patterns of presentation. Among these patterns, high but transient antigen stimulus results in the weakest CAR-T cell response. Figure 2B shows the secretion capacity of potent effector cytokines by CAR-T cells at varying antigen densities for 24 hrs (26). Figure 2C depicts the dynamic profiles of input, regulator, and output (27). The y-axe in figures is the fold-change from baselines (assumed to 1). Time is in arbitrary units in all plots. Using typical T cell regulation rate, the response time is in the range of minutes to hours.
response (Figure 2B, second row). Exponentially increasing antigen stimulus yields the strongest response (Figure 2B, bottom row). T cells discriminate antigens through their dynamics. This theory has been supported by the experimental observations that the effector cells, including CAR-T cells, most effectively respond to antigenic threats with high changing rate (8, 14). CAR-T cell responses therefore depend not only upon the design of CAR and the T cells, but also upon the stimulatus patterns of their target antigen. The stimulus patterns of the target antigen to CAR-T cells is a function of tumor burden, anatomical site, antigen shedding level, and the heterogeneity in antigen-expression cells, among others. Overall, the presentation dynamics of target antigen can lead to highly variable CAR-T cell responses, which may result in high clinical variation and contribute to the discrepancy between hematological malignancies and solid tumor efficacy.

CAR-T Cells Have Restricted Activation in Solid Tumors

Translating the efficacy of CAR-T cell therapy in hematological malignancies to solid tumors is a multifaceted challenge. CAR-T cell therapy has not yet shown reproducible clinical efficacy in solid tumors. Although anti-CD19 CAR-T cells undergo expansion post-infusion in most patients, CAR-T expansion has not been observed to the same extent in patients with solid tumors. We speculate it is because anti-CD19 CAR-T cells encounter their target antigen more readily than is the case in solid tumors. Due to their anatomical locations (most reside in the lymphoid tissues), hematological cancer cells encounter CAR-T cells and are expected to expose their target antigen to CAR-T cells more rapidly and frequently (Figure 3A). As a result, CAR-T cells are often extensively activated and exhibit considerable efficacy in hematological malignancies.

Unfortunately, CAR-T cells face additional challenges in solid tumor patients immediately after injection. First, there is a lack of highly tumor selective targets. Unlike the hematological antigens (e.g., CD19, CD22, and BCMA), most solid tumor-associated antigens are enriched in tumors but also shared by normal tissues. Whilst trafficking to tumor sites, on-target off-tumor expression may cause more chronic activation (CA) of CAR-T cells (Figure 3A). Solid tumors can also shed antigens into circulation, which may partially trigger CAR-T cells and cause chronic activation before tumor and exhaustion (38). Secondly, solid tumors consist of diverse cell populations with varying

![Figure 2](https://example.com/figure2.png)
degrees of target expression. It is highly possible that CAR-T cells, after extravasation, have constrained access to highly antigen-expressing cells and are exposed to a diluted antigen pool (HTA, Figure 3A). As such, CAR-T cells are likely stimulated chronically in the tumor bed, resulting in a higher probability of exhaustion. Thirdly, the tumor microenvironment can drastically alter CAR-T cell function (TIM, Figure 3A). Compared to hematological malignancies, solid tumor microenvironments challenge CAR-T cells with hypoxic, acidic, and nutrient-poor conditions that contribute to altered metabolism and accelerated exhaustion. Furthermore, the abundance of immunosuppressive cells further impairs CAR-T function via presentation and secretion of immunosuppressive ligands and molecules.

We contextualize the model with these negative factors and evaluate their effects on CAR-T cell response. In addition to the diluted and chronic profiles of antigenic stimulation in solid tumors, we set a higher regulator (Y) production rate to reflect the immunosuppressive factors in the tumor microenvironment. As shown in Figure 3B, owing to the distinct antigenic presentation dynamics, CAR-T cells show a markedly dampened response in solid tumors compared to hematological malignancies.

We further verified our model prediction with clinical data. We surveyed the cellular kinetics of CAR-T cells in seven clinical trial cohorts of cancer patients (five hematological and two solid tumors) and extracted data including maximal proliferation (highest concentration of CAR copies in the blood), proliferation duration (time from injection to peak concentration), and contraction rate (slope of decline following the initial peak) across multiple CAR products and tumor types (37). These trials included 217 patients and 22 of which were from the solid tumor trials. Two solid tumors are glioblastoma and non-small cell lung cancer, treated with anti-EGFRvIII and anti-EGFR CAR-T cell therapies, respectively. Despite high inter-subject variabilities, we found that in solid tumors, CAR-T cells exhibited restricted proliferation potential (Figure 3C, left) and significantly shortened proliferation duration (Figure 3C, middle), whereas their contraction rates were significantly elevated (Figure 3C, right) compared to hematological tumors, consistent with our theoretical predictions in Figure 3B. These clinical observations support our model predictions to show CAR-T dampened activations in solid tumors. The diluted and chronic dynamic nature of antigen stimulus in solid tumors, coupled with the
confluence of immunosuppressive factors, impose limited efficacy on CAR-T cell therapy in solid tumors.

**CAR Therapeutic Strategies Confer Differential Benefit to CAR-T Therapy**

Multiple CAR engineering and therapeutic approaches are under active investigation to enhance CAR-T cell function in vivo. These strategies include combining CAR-T cell therapy with checkpoint blockade or other tumor immune modulators, cytokine-secreting “armored” CAR-T cells, CARs with OR logic gates, and regional injection of CAR-T cells (39, 40). Many of these approaches have shown promise for overcoming certain obstacles in solid tumors. We revisited these strategies and estimated their potentials and limitations for improving CAR-T cell responses against solid tumors under the “discontinuity theory.”

Immune checkpoint blockade can partially augment CAR-T cell therapy by counteracting the immune inhibitory receptors (41). In non-Hodgkin lymphomas, patients who initially failed to respond or relapsed to CD19 CAR-T therapy showed re-expanded CAR-T cells after a sequential treatment with the anti-PD1 inhibitor pembrolizumab (42, 43). This partial synergistic combination is also captured within “discontinuity theory” (Figure 4A). The magnitude of synergy depends on the fraction of exhausted CAR-T cells amenable to reinvigoration by checkpoint blockade, which can be highly variable in the clinic. It explains why checkpoint blockade does not consistently enhance CAR-T cell responses (44). Secondly, CAR-T cells must overcome the immunosuppressive microenvironments of solid tumors. Therapies that counteract immunosuppressive factors could be indispensable to achieving optimal effector function of CAR-T cells. Strategies such as targeting immunosuppressive cell types (Tregs, TAMs) or inhibiting immunosuppressive factors (e.g., TGF-β, IDO) have been preliminarily explored. These strategies can reprogram or normalize the tumor microenvironment to be more permissive to CAR-T cell effector functions (Figure 4B).

Thirdly, intralesional injection has been employed to circumvent poor CAR-T cell trafficking and infiltration (45). Local CAR-T cell delivery in solid tumors, in addition to boosting CAR-T cell accumulation within tumors, may also partially avoid chronic activation before tumor by non-tumor antigens (Figure 4C). Currently, however, regional injections are primarily used for glioblastomas and malignancies with pleural or peritoneal spreading. Finally, multi-specific CAR with “OR” logic gates can activate CAR-T cells in the presence of either targeted antigen, partially overcoming heterogeneous expression of target antigens within the tumor (Figure 4D). Overall, our model corroborates the potential of each strategy to improve CAR-T cell responses in solid tumors, although no individual strategy alone seems capable of boosting CAR-T response levels to those comparable with what we observed in hematological tumors.

The journey of CAR-T cells driving to solid tumors is riddled with roadblocks. Together, these roadblocks impinge CAR-T cells’ overall trafficking into solid tumors in a potentially redundant manner, such that individual roadblocks may act as independently rate-limiting steps even when others are cleared. Based on our predictions, combination strategies that overcome multiple roadblocks may be a promising path toward achieving robust benefit of CAR-T cell therapy in solid tumors (Figures 4E, F).

**DISCUSSION**

CAR-T cell therapy has become a revolutionary treatment in light of their remarkable efficacy in hematologic malignancies.
Unfortunately, in patients with solid tumors, consistent responses to CAR-T cell therapy are still limited. The use of an antigen-binding antibody fragment in CARs enables CAR-T cells to recognize and kill tumor cells independently of the major histocompatibility complex (MHC). Incorporating a costimulatory receptor domain (CD28 or 4-1BB) into the CAR allows CAR-T cells to respond independently of costimulatory signaling. However, the conventional design of CARs does not preclude the onset of multiple co-inhibitory signaling mechanisms, nor does it avoid the harshly immunosuppressive tumor microenvironment. As a result, CAR T cell exhaustion is augmented and efficacy is diminished against solid tumors. Removal of one of the genes encoding these co-inhibitory receptors, such as PD-1 (PDCD1), has shown the potential to improve antitumor immunity (46, 47).

It is well documented that T cell dysfunction and exhaustion are prevalent in solid tumors. Like physiological T cells, CAR-T cells are susceptible to chronic antigenic stimulation and exhaustion. In this study, we applied an IFFL to the “discontinuity theory” of the immune system to assess the dynamics of antigen presentation and its consequence on CAR-T cell response and exhaustion. Our findings highlighted that chronic activation (CA) before tumor and diluted (HTA) antigenic stimulation, as well as the tumor immunosuppressive microenvironment (TIM), can significantly restrain CAR-T cell responses against solid tumors. The antigen presentation rate (the number of antigens presented to each CAR-T cell per unit of time) and the location of malignant cells both critically affect the exhaustion and response of CAR-T cells.

Although insufficient antigen access leads to CAR-T cells’ poor functions in solid tumors, excess antigen stimulation or too high tumor burdens may also result in dysfunctions of CAR-T cells. There is likely a goldilocks of antigen stimulation for CAR-T cells, where CAR-T cells should be appropriately stimulated to function but are not overwhelmed by the amount of tumor antigens. Resistance to CD19 CAR T-cell often develops in patients with high tumor burdens (48). Excess costimulation or CAR with very high target affinity does not always translate to better clinical outcomes (18, 49). Consistent with this observation, increasing CAR affinity is known to promote T cell exhaustion and decrease the generation of memory-phenotype cells (50). The model suggests that the proper magnitudes and temporal dynamics of antigen presentation are essential for an efficient CAR-T cell therapy, which yields multiple implications for patient selection and CAR designs.

Multiple therapeutic approaches to enhance CAR-T cells efficacy against solid tumors are under active investigation. The therapeutic promise of these approaches has been preliminarily observed in certain solid malignancies (51, 52). However, translating the dramatic efficacy of CAR-T cells in hematological settings into solid tumor contexts remains challenging. We contextualized these therapeutic approaches with an IFFL and investigated their potential to enhance CAR-T cell responses. Interestingly, we found each of these approaches was individually effective but insufficient to boost CAR-T responses against solid tumors, as they clear but one of the many roadblocks CAR-T cells face on their journey toward efficacy in solid tumors. For instance, combining checkpoint blockades with CAR-T cell therapies could partially reverse CAR-T cell exhaustion (41). Still, such a combination has not significantly benefited CAR-T cell functions in solid tumors yet (53). Checkpoint blockades may release the brakes from suppressed CAR-T cells, but such a combination is insufficient to induce T cells infiltration and reverse the immunosuppressive factors in solid tumors. Therefore, as our model implicates, studies combining multiple mitigating strategies may be necessary to result in T cell infiltration, activation, and effector function in complex solid tumors (54).

Our reductionist modeling approach for CAR-T cell activation is primarily a proof-of-concept, which comes with limitations. CAR-T cell activation and exhaustion are highly complex biological processes that involve many phenotypic, transcriptional, and epigenetic alterations. Our model only considers the antigen-dependent CAR-T cell simulation. Antigen-independent CAR-T cell activation (55) and high levels of tonic signaling due to CAR aggregation (56, 57) can also induce CAR-T cell exhaustion. This further obfuscates the balance between CAR-T cell activation and exhaustion. Our model does not explicitly integrate these regulatory factors, considering these immunosuppressive factors may occur on different spatiotemporal scales. Although it can improve model fidelity, integrating these factors into the model requires more quantitative investigations of these regulatory factors, which are unfortunately still emerging. Tonic CAR signaling, triggered by clustering of CAR, can induce early exhaustion of CAR T cells. Different costimulatory domains may confer different sensitivity to exhaustion induced by persistence CAR signaling; for instance, CD28 appears to augment, while 4-1BB ameliorates, exhaustion induced by CAR clustering. In addition to antigen dynamics, this balance is also a function of CAR affinity for antigens, antigen density on target cells, and the nature of intracellular costimulatory domains, each of which can enhance or reduce CAR-T cell activation. More theoretical and experimental investigations into these aspects are warranted to score a clinically meaningful strike against solid tumors.

**AUTHOR CONTRIBUTIONS**

Conceptualization: YC. Investigation: CL. Analysis: CL. Writing-original draft preparation: YC and CL. Writing-review and editing: YC, CL, TQ, JM, and YL. Supervision: YC. Funding acquisition: YC. All authors have read and agreed to the published version of the manuscript.

**FUNDING**

This study was funded by National Institute of Health (GM119661).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.748768/full#supplementary-material
REFERENCES

1. Weber EW, Maus MV, Mackall CL. The Emerging Landscape of Immune Cell Therapies Cell. Cell (2020) 181(1):46–62. doi: 10.1016/j.cell.2020.03.001

2. Majzner RG, Mackall CL. Clinical Lessons Learned From the First Leg of the CAR T Cell Journey. Nat Med (2019) 25(9):1341–55. doi: 10.1038/s41591-019-0564-6

3. Martinet M, Moon EK. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol (2019) 10:128. doi: 10.3389/fimmu.2019.00128

4. Wei J, Han X, Bo J, Han W. Target Selection for CAR-T Therapy. J Hemat Oncol (2019) 12(1):62. doi: 10.1186/s13045-019-0758-x

5. Yi JS, Cox MA, Zajac AJ. T-Cell Exhaustion: Characteristics, Causes and Conversion. Immunology (2010) 129(4):474–81. doi: 10.1111/j.1365-2567.2010.03255.x

6. Eberl G, Pradeau T. Towards a General Theory of Immunity? Trends Immunol (2018) 39(4):261–3. doi: 10.1016/j.it.2017.11.004

7. Pradeu T, Jaeger S, Vivier E. The Speed of Change: Towards a Discontinuity Theory of Immunity? Nat Rev Immunol (2013) 13(10):764–9. doi: 10.1038/nnr3521

8. Pradeu T, Vivier E. The Discontinuity Theory of Immunity. Sci Immunol (2016) 1(1):AAG0479. doi: 10.1126/sciimmunol.aag0479

9. Sontag ED. A Dynamic Model of Immune Responses to Antigen Presentation Predicts Different Regions of Tumor or Pathogen Elimination. Cell Syst (2017) 4(2):231–241.e11. doi: 10.1016/j.cels.2016.12.003

10. Mamonkin M, Brenner MK. Reversal of Exhaustion in Engineered T Cells. Frontiers in Immunology | www.frontiersin.org October 2021 | Volume 12 | Article 748768

11. Pauken KE, Wherry EJ. Overcoming T Cell Exhaustion in Infection and Cancer. Trends Immunol (2015) 36(4):265–76. doi: 10.1016/j.it.2015.02.008

12. Thommen DS, Schumacher TN. T Cell Dysfunction in Cancer. Cancer Cell (2018) 33(4):547–62. doi: 10.1016/j.ccell.2018.03.012

13. Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining ‘T Cell Exhaustion’. Nat Rev Immunol (2019) 19(11):665–70. doi: 10.1038/s41577-019-0221-9

14. Trendel N, Kruger P, Gaglione S, Nguyen J, Pettmann J, Sontag ED, et al. Perfect Adaptation of CD8+ T Cell Responses to Constant Antigen Input Over a Wide Range of Affinities is Overcome by Costimulation. Sci Signal (2021) 14(666):eaay9363. doi: 10.1126/scisignal.aaay9363

15. Haldane JS. The Physiological Significance of Weber’s Law and Colour Contrast in Vision. J Physiol (1933) 79(2):121–38. doi: 10.1113/jphysiol.1933.sp003034

16. Osterhout WJ. Antagonism and Weber’s Law. Science (1916) 44(1131):318–20. doi: 10.1126/science.44.1131.318

17. Majzner RG, Mackall CL. Tumor Antigen Escape From CAR-T Cell Therapy. Cancer Discov (2018) 8(10):1219–26. doi: 10.1158/2159-8290.CD-18-0442

18. Wijewarnasuriya D, Bebernitz C, Lopez AV, Dotti G, Brenner MK. Addition of the CD28 Signaling Domain to Chimeric T-Cell Receptors Enhances Chimeric T-Cell Resistance to T Regulatory Cells. Leukemia (2006) 20(10):1819–28. doi: 10.1038/sj.leu.2404366

19. Cherkassky L, Morello A, Villena-Vargas J, Fung Y, Dimitrov DS, Jones DR, et al. Human CAR T Cells With Cell-Intrinsic PD-1 Checkpoint Blockade Resist Tumor-Mediated Inhibition. J Clin Invest (2016) 126(8):3130–44. doi: 10.1172/JCI83092

20. Harris DT, Hager MV, Smith SN, Cai Q, Stone JD, Kruger P, et al. Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains. J Immunol (2018) 200(3):1088–100. doi: 10.4049/jimmunol.1700236

21. Goentoro L, Shoval O, Kirschner MW, Alon U. The Incoherent Feedforward Loop Can Provide Fold-Change Detection in Gene Regulation. Mol Cell (2009) 36(5):894–9. doi: 10.1016/j.molcel.2009.11.018

22. Wherry EJ, Kurachi M. Molecular and Cellular Insights Into T Cell Exhaustion. Nat Rev Immunol (2015) 15(8):486–99. doi: 10.1038/nri3862

23. Greenman R, Pizam Y, Cohen MH, Horev G, Denkberg G, Orr SS, et al. Phenotypic Models of CAR-T Cell Activation Elucidate the Pivotal Regulatory Role of CAR Down-Modulation. Mol Cancer Ther (2021) 20(5):946–57. doi: 10.1158/1535-7163.MCT-19-1110

24. Li W, Qiu S, Chen J, Jiang S, Chen W, Jiang J, et al. Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy. Immunity (2020) 53(2):456–467.e6. doi: 10.1016/j.immuni.2020.07.011

25. Kreieder M, Barrett I, Bendtsen B, Brennan D, Kolch W. Signaling Dynamics Regulating Crosstalks Between T-Cell Activation and Immune Checkpoints. Trends Cell Biol (2021) 31(3):224–35. doi: 10.1016/j.tcb.2020.12.001

26. Garca AR, Palazon A, Ortega EN, Powell DJ, Guedan S. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape. Front Immunol (2020) 11:1109. doi: 10.3389/fimmu.2020.01109

27. Li W, Rui W, Xiao Z, Liu X. Enhancing CAR-T Cell Efficacy in Solid Tumors by Targeting the Tumor Microenvironment. Cell Mol Immunol (2021) 18(3):1085–95. doi: 10.1042/cmii202100655-2

28. Chen J, Moyado IF, Seo H, Lio CJ, Hemplman LJ, Sekiya T, et al. NRAA Transcription Factors Limit CAR T Cell Function in Solid Tumours. Nature (2019) 567(7749):530–40. doi: 10.1038/s41586-019-0985-x

29. Weber EW, Parker KR, Sotillo E, Lynn BC, Anbunathan H, Lattin J, et al. Transient Rest Restores Functionality in Exhausted CAR-T Cells Through Epigenetic Remodeling. Science (2021) 372(6537):eabc1786. doi: 10.1126/science.abc1786

30. Ferrell JE. Perfect and Near-Perfect Adaptation in Cell Signaling. Cell Syst (2016) 2(2):62–7. doi: 10.1016/j.cels.2016.02.006

31. Liu C, Ayyar VS, Zheng X, Chen W, Zheng S, Mody H, et al. Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells in Humans. Clin Pharmacol Therol (2021) 109(3):716–27. doi: 10.1002/cpt.2040

32. Sun L, Gao F, Gao Z, Ao L, Li N, Ma S, et al. Shed Antigen-Induced Blocking Effect on CAR-T Cells Targeting Glypican-3 in Hepatocellular Carcinoma. J Immunother Cancer (2021) 9(4):e001875. doi: 10.1136/jitc-2020-001875

33. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The Future of Cancer Immunotherapy With CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. J Immunother Cancer (2019) 36(5):471–82. doi: 10.1016/j.jcimmunol.2019.09.006

34. Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, et al. GD2-Specific CAR T Cells Undergo Potent Activation and Deletion Following
Antigen Encounter But can be Protected From Activation-Induced Cell Death by PD-1 Blockade. *Mol Ther* (2016) 24(6):1135–49. doi: 10.1038/mt.2016.83

Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. *Clin Cancer Res* (2017) 23(9):2255–66. doi: 10.1158/1078-0432.CCR-16-1300

Wei J, Luo C, Wang Y, Guo Y, Dai H, Tong C, et al. PD-1 Silencing Impairs the Anti-Tumor Function of Chimeric Antigen Receptor Modified T Cells by Inhibiting Proliferation Activity. *J Immunother Cancer* (2019) 7(1):209. doi: 10.1186/s40425-019-0685-y

Theruvath J, Sotillo E, Mount CW, Graef CM, Delaidelli A, Heitzeneder S, et al. Locoregionally Administered B7-H3-Targeted CAR T Cells for Treatment of Atypical Teratoid/Rhabdoid Tumors. *Nat Med* (2020) 26(5):712–9. doi: 10.1038/s41591-020-0821-8

Singh N, June CH. Boosting Engineered T Cells. *Science* (2019) 365(6499):119–20. doi: 10.1126/science.aax6331

Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-Engineered T Cells in Patients With Refractory Cancer. *Science* (2020) 367(6481):eaba7365. doi: 10.1126/science.aba7365

Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, et al. Tumor Interferon Signaling and Suppressive Myeloid Cells are Associated With CAR T-Cell Failure in Large B-Cell Lymphoma. *Blood* (2021) 137(19):2621–33. doi: 10.1182/blood.2020007445

Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, et al. Enhanced CAR T Cell Expansion and Prolonged Persistence in Pediatric Patients With ALL Treated With a Low-Affinity CD19 CAR. *Nat Med* (2019) 25(9):1408–14. doi: 10.1038/s41591-019-0549-9

Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, et al. Calibration of CAR Activation Potential Directs Alternative T Cell Fates and Therapeutic Potency. *Nat Med* (2019) 25(3):530. doi: 10.1038/s41591-019-0360-3

Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Anti-Tumor Activity in Solid Malignancies. *Cancer Immunol Res* (2014) 2(2):112–20. doi: 10.1158/2326-6066.CIR-13-0170

Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, et al. Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation and Augments Prostate Cancer Eradication. *Mol Ther* (2018) 26(7):1855–66. doi: 10.1016/j.ymtl.2018.05.003

Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley R, et al. CAR T Cells Administered in Combination With Lymphodepletion and PD-1 Inhibition to Patients With Neuroblastoma. *Mol Ther* (2017) 25(9):2214–24. doi: 10.1016/j.ymtl.2017.05.012

Sterner RC, Sterner RM. CAR-T Cell Therapy: Current Limitations and Potential Strategies. *Blood Cancer J* (2021) 11(4):69. doi: 10.1038/s41408-021-00459-7

Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, et al. Antigen-Independent Activation Enhances the Efficacy of 4-1BB-Costimulated CD22 CAR T Cells. *Nat Med* (2021) 27(5):842–50. doi: 10.1038/s41591-021-01326-5

Hege K. Context Matters in CAR T Cell Tonic Signaling. *Nat Med* (2021) 27(5):763–4. doi: 10.1038/s41591-021-01340-7

Long AH, Haso WM, Sherm JP, Wanahanen KM, Murgai M, Ingaramo M, et al. 4-1BB Costimulation Amplifies T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors. *Nat Med* (2015) 21(6):581–90. doi: 10.1038/nm.3838

**Conflict of Interest:** TQ owns equity in Humanigen, a biopharmaceutical company.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.